Association between computed tomography-based adipose tissue parameters and liver transplant outcomes in patients with hepatocellular carcinoma.
Hu Z., Chen H., Lin Z., He C., Shen W., Li H.
Retrospective Study with a reported sample of 765, published in Clin Nutr (2025) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Retrospective Study
- Journal
- Clin Nutr (2025)
- Country
- England
- Reported sample size
- 765
- Source database
- PubMed
- PMID
- 40743774
- DOI
- 10.1016/j.clnu.2025.07.015
Abstract (original English)
The prognostic value of skeletal muscle in liver transplant recipients with hepatocellular carcinoma (HCC) has been documented; however, the role of adipose tissue remains ambiguous. This study aimed to evaluate the association between adipose tissue and transplant outcomes in patients with HCC. A total of 765 patients with HCC who underwent liver transplantation (LT) at 3 transplant centers were included in this retrospective study. Computed tomography (CT) scans were utilized to quantify the area and radiodensity of visceral and subcutaneous adipose tissue. Cut-off values for adipose tissue parameters were determined based on tertiles. The Cox proportional hazards models were established to identify the predictors of overall survival (OS) and tumor recurrence. Median age at transplant was 53 years, most were male (89.0 %) and cirrhotic (91.7 %). The median follow-up was 40.3 months. In univariate survival analysis, patients with high subcutaneous adipose tissue radiodensity (SATr) (>-86.5 HU) exhibited significantly lower 5-year OS rates than those with low SATr (49.9 % vs. 65.3 %, P < 0.001). Adjusted analyses revealed that high SATr independently predicted increased mortality (HR, 1.498; 95 % CI, 1.175-1.909; P = 0.001). SATr significantly increased during the first month postoperatively (P < 0.001), with one-third of the patients exhibiting an SATr change rate exceeding 10
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • Without an adequate control group, treatment effects cannot be separated from other factors.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.